By David Tuller, DrPH Embedding ME/CFS in NIH's RECOVER initiative Ian Lipkin is a well-known professor of epidemiology at Columbia University and director of the Center for Solutions for ME/CFS, funded by the U.S. National Institutes of Health (NIH). In a recent opinion piece for STAT, he and ME/CFS patient ...

By David Tuller, DrPH In November, 2023, journalists Betsy Ladyzhets and Miles Griffis launched The Sick Times, a publication whose tagline is “chronicling the Long Covid crisis.” Since then, the publication has diligently tracked the political and medical developments of this post-pandemic pandemic and has become a go-to source for ...

By David Tuller, DrPH The Cochrane mess, which I wrote about the other day, is threatening to take on a life of its own. Perhaps Cochrane thinks the fuss over the big Christmas “fuck you” it delivered to members of the ME/CFS community will blow over quickly. That could happen, ...

By David Tuller, DrPH If the results for a trial’s primary outcome do not meet the threshold for what is considered a “clinically significant” benefit, it goes without saying—or at least it should--that investigators have no legitimate grounds for promoting their intervention as “effective.” This is especially true when the ...

By David Tuller, DrPH I have written frequently about Cochrane, the organization renowned for its systematic reviews of medical interventions, and its deeply flawed review of exercise therapies for ME/CFS--including its decision last month to abandon its commitment to produce a new version. Now Hilda Bastian, an Australia health consumer ...